Compare Quest Diagnostics Inc (DGX) vs Las Vegas Sands Corp. (LVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Las Vegas Sands Corp. — how do they compare? Quest Diagnostics Inc trades at $230.97 (market cap $25.48B), while Las Vegas Sands Corp. trades at $36.17 (market cap $23.38B). The key difference: Quest Diagnostics Inc and Las Vegas Sands Corp. are close in size by market cap, and Las Vegas Sands Corp. pays the higher dividend (3.32%). Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Las Vegas Sands Corp. for 72 Days on average.
| DGX | LVS | |
|---|---|---|
Market Cap | $25.48B | $23.38B |
Volume | 941,866 | 6,994,661 |
Sector | Health | Consumer Cyclical |
52-Week High | $247.45 | $69.49 |
52-Week Low | $173.49 | $35.81 |
Typical Hold Time | 56 Days | 72 Days |
Enterprise Value | $31.23B | $35.27B |
Dividend Yield | 1.49% | 3.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.81, up 1.68% with strong year-to-date performance driven by organic growth and advanced diagnostics adoption. The company has consistently beaten earnings expectations in recent quarters with Q2 2026 EPS of $3.12 exceeding estimates. Technical indicators show a bearish bias while fundamentals remain solid with 9.19% net margin and 14.35% ROE. Recent developments include a partnership with Apple Health app and positive clinical study results.
DGX presents a mixed outlook with strong fundamental performance offset by technical weakness and regulatory headwinds. The 38% upside to consensus price target of $250 offers potential, but Medicare reimbursement cuts and bearish technical signals warrant caution. Growth in consumer testing and strategic partnerships provide catalysts, though execution risks and debt levels require monitoring.
LVS trades at $36.10, up 0.81% with a bearish technical signal despite recent earnings beats. The company shows strong fundamentals with $13.02B revenue, 12.59% net margin, and positive cash flow of $191M in 2025. Recent news highlights Sands China's community initiatives and operational milestones, while analyst consensus remains strongly bullish with a $59.78 price target.
LVS presents a compelling value opportunity with attractive valuation multiples (P/E 13.99, EV/EBITDA 7.64) and robust profitability (ROE 134.29%). However, high debt levels and recent Q2 2026 earnings miss pose risks. The significant upside to analyst targets suggests potential for substantial returns if operational execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Las Vegas Sands Corp.
Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner, Four Seasons Hotel Macao, and Parisian in Macao, and the Marina Bay Sands resort in Singapore. Its Venetian and Palazzo Las Vegas in the U.S. asets were sold to Apollo and VICI for $6.25 billion in 2022. We expect Sands to open a fourth tower in Singapore in 2026. After the sale of its Vegas assets, the company will generate all its EBITDA from Asia, with its casino operations generating the majority of sales.
Read more on LVS →
